Novel sources of Flavor Changed Neutral Currents in the 331RHN331_{RHN} model

Sources of Flavor Changed Neutral Currents (FCNC) naturally emerge from a well motivated framework called 3-3-1 with right-handed neutrinos model, $331_{RHN}$ for short, mediated by an extra neutral gauge boson $Z^{\prime}$. Following previous works we calculate these sources and in addition we derive new ones coming from CP-even and -odd neutral scalars which appear due to their non-diagonal interactions with the physical standard quarks. Furthermore we show that bounds related to the neutral mesons systems $K_L-K_S$ and $D_1^0 - D_2^0$ may be significantly strengthened in the presence of these new interactions allowing us to infer stronger constraints on the parameter space of the model.Comment: Published version. 10 pages, 6 figure

The 3-3-1 model with S_4 flavor symmetry

We construct a 3-3-1 model based on family symmetry S_4 responsible for the neutrino and quark masses. The tribimaximal neutrino mixing and the diagonal quark mixing have been obtained. The new lepton charge \mathcal{L} related to the ordinary lepton charge L and a SU(3) charge by L=2/\sqrt{3} T_8+\mathcal{L} and the lepton parity P_l=(-)^L known as a residual symmetry of L have been introduced which provide insights in this kind of model. The expected vacuum alignments resulting in potential minimization can origin from appropriate violation terms of S_4 and \mathcal{L}. The smallness of seesaw contributions can be explained from the existence of such terms too. If P_l is not broken by the vacuum values of the scalar fields, there is no mixing between the exotic and the ordinary quarks at the tree level.Comment: 20 pages, revised versio

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

Global Retinoblastoma Presentation and Analysis by National Income Level

Importance: Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child's life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale. Objectives: To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis. Design, Setting, and Participants: A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017. Main Outcomes and Measures: Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis. Results: The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4) were female. Most patients (n = 3685 84.7%) were from low-and middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 62.8%), followed by strabismus (n = 429 10.2%) and proptosis (n = 309 7.4%). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 95% CI, 12.94-24.80, and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 95% CI, 4.30-7.68). Conclusions and Relevance: This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs. © 2020 American Medical Association. All rights reserved

International Journal of Modern Physics A

185020

Preguntas y respuestas relacionadas con tabaquismo en pacientes con EPOC. Aplicación de metodología con formato PICO

The ALAT and SEPAR Treatment and Control of Smoking Groups have collaborated in the preparation of this document which attempts to answer, by way of PICO methodology, different questions on health interventions for helping COPD patients to stop smoking. The main recommendations are: (i) moderate-quality evidence and strong recommendation for performing spirometry in COPD patients and in smokers with a high risk of developing the disease, as a motivational tool (particularly for showing evidence of lung age), a diagnostic tool, and for active case-finding; (ii) high-quality evidence and strong recommendation for using intensive dedicated behavioral counselling and drug treatment for helping COPD patients to stop smoking; (iii) high-quality evidence and strong recommendation for initiating interventions for helping COPD patients to stop smoking during hospitalization with improvement when the intervention is prolonged after discharge, and (iv) high-quality evidence and strong recommendation for funding treatment of smoking in COPD patients, in view of the impact on health and health economics. © 2017 SEPA

Preguntas y respuestas relacionadas con tabaquismo en pacientes con EPOC. Aplicación de metodología con formato PICO

The ALAT and SEPAR Treatment and Control of Smoking Groups have collaborated in the preparation of this document which attempts to answer, by way of PICO methodology, different questions on health interventions for helping COPD patients to stop smoking. The main recommendations are: (i) moderate-quality evidence and strong recommendation for performing spirometry in COPD patients and in smokers with a high risk of developing the disease, as a motivational tool (particularly for showing evidence of lung age), a diagnostic tool, and for active case-finding; (ii) high-quality evidence and strong recommendation for using intensive dedicated behavioral counselling and drug treatment for helping COPD patients to stop smoking; (iii) high-quality evidence and strong recommendation for initiating interventions for helping COPD patients to stop smoking during hospitalization with improvement when the intervention is prolonged after discharge, and (iv) high-quality evidence and strong recommendation for funding treatment of smoking in COPD patients, in view of the impact on health and health economics. © 2017 SEPA

Toxicological effects and resistance to pyrethroids in Boophilus microplus from Goiás, Brazil Efeitos toxicológicos e resistência a piretróides em Boophilus microplus de Goiás

In order to monitor the susceptibility of Boophilus microplus to acaricides and improve control measures, the effects of cypermethrin, deltamethrin and permethrin on larvae obtained in the city of Goiânia in the Brazilian state of Goiás were studied. Although these pyrethroids are already sold as acaricides, their cost-benefit efficiency has been questioned. Fasting 14-21 day-old larvae were immersed in solutions of the acaricides under test, maintained at 27±1° C, and relative humidity over 80%, and observed under the stereoscope within an apparatus originally designed for studying the non-parasitic phase of the tick life cycle. The observed toxicological effects were: excitability, repetitive motion, decreased motor ability, detachment, paralysis, knock-down and cuticular proliferation of liquids and gases. The materials used in the manufacture of this apparatus consisted of disposable Petri dishes, "organza" cloth and paraffin, none of which are toxic to tick larvae. Mean death rates after 24h were 76.3%, 87.5%, 77.6%, 91.2%, 86.2% and 100% for 25 and 50ppm deltamethrin, 150 and 300ppm cypermethrin and 1250 and 2500ppm permethrin, respectively. The ticks were resistant to commercial concentrations of deltamethrin and cypermethrin. Only 2500ppm permethrin produced the mortality recommended by the Brazilian Ministry of Agriculture.<br>Estudaram-se os efeitos de cipermetrina, deltametrina e permetrina sobre larvas de uma cepa de campo de Goiânia, com o objetivo de monitorar a susceptibilidade de Boophilus microplus para esses acaricidas e fomentar medidas de controle. Larvas em jejum com 14 a 21 dias, imersas em soluções desses piretróides, foram mantidas a 27±1°C e UR% > ou = 80% e observadas por 24h ao estereoscópio, contidas em dispositivo desenvolvido originalmente para estudos da fase não parasitária do ciclo evolutivo. O material utilizado em sua confecção, placa de petri descartável, tecido organza e parafina, não foi tóxico para as larvas. Os seguintes efeitos toxicológicos foram observados: excitabilidade, movimentação repetitiva, diminuição da capacidade locomotora, desprendimento, paralisia, knock-down e proliferação cuticular de líquidos e gases. A mortalidade média na 24ªh foi de 76,3%, 87,5%, 77,6%, 91,2%, 86,20%, e 100,0%, respectivamente, para deltametrina 25ppm e 50ppm, cipermetrina 150ppm e 300ppm e permetrina 1250ppm e 2500ppm. O ixodídeo foi resistente às concentrações comerciais de deltametrina e cipermetrina. Apenas permetrina 2500ppm provocou índice de mortalidade superior ao valor recomendado pelo Ministério da Agricultura para acaricidas